MedPath

adding memantine to treatment of schozopherenia

Phase 3
Conditions
schizopherenia.
Schizophrenia
Registration Number
IRCT20180301038906N1
Lead Sponsor
Mashhad University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Schizophrenia in the relative recovery period
Use of atypical antipsychotics including risperidone and olanzapine
No other drugs (except anticholinergic and benzodiazepine)
Lack of pregnancy or breastfeeding
No serious organic disease and no drug use at the time of entering the study

Exclusion Criteria

There is serious organic disease
Pregnancy or breastfeeding
Existence of dementia

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The condition of psychotic symptoms. Timepoint: Week 2,4,6. Method of measurement: wechsler.
Secondary Outcome Measures
NameTimeMethod
Cognitive and negative symptoms. Timepoint: week 2,4,6. Method of measurement: wechsler.
© Copyright 2025. All Rights Reserved by MedPath